Navigation Links
Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
Date:7/20/2009

London, July 20 /PRNewswire/ -- There has been a recent upsurge in Merger & Acquisition (M&A) activities in the pharmaceutical and biotechnology space. While the economic downturn and related credit crunch has had an impact, this alone cannot account for the recent M&A mania, which has including four mega M&As in the first half of 2009.

(Logo:http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

"The real intention behind these mergers remains a question, as past mergers have not yielded substantial value addition in terms of R&D productivity," says Frost & Sullivan Senior Research Analyst Ranjith Gopinathan.

To look at these Mergers & Acquisitions in the Pharmaceutical and Biotechnology industry, the Healthcare Group at Frost & Sullivan will be hosting a complimentary Analyst Briefing Presentation on Tuesday, 28th July 2009, at 2 p.m. BST/ 1 p.m. GMT.

Highlights of this briefing will include an analysis of the factors contributing to the increasing consolidation in the market, the impact of the economic downturn, as well as funding sources for biotech companies. The briefing will also look at key restraints for M&A activities in the pharma-biotech industry and provide a future M&A outlook. The discussion will benefit venture capitalists, investment banks, pharma and biotech companies as well as academic institutions.

"The global downturn's detrimental impact on funding availability coupled with an average 30 per cent decline in the value of biotech firms, means that outright acquisitions rather than complex licensing deals are an attractive proposition," concludes Gopinathan.

To participate in this briefing, please email Patrick Cairns at

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
2. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
3. Pharmacyclics Announces Subscription Price for Rights Offering
4. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
5. Simcere Pharmaceutical Group Notice of Annual General Meeting
6. Amylin Pharmaceuticals to Webcast Second Quarter Results
7. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
8. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
9. ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference
10. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
11. ParagonRx Creates New Website Featuring REMS Help Center for Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)MELVILLE, N.Y., Dec. 3 Nikon Corporation, an innovator of advanced optical instruments, announced today that it has signed a licensing agreement with Harvard University granting Nikon the rights to u
(Date:12/3/2009)SAN FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today anno
(Date:12/3/2009)TUSTIN, Calif., Dec. 3 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it will release its financial results for the second quarter of fiscal year 2010 on December 10, 2009 at 7
(Date:12/3/2009)HOPKINTON, Mass., Dec. 3 Caliper Life Sciences, Inc. (Nasdaq: CALP ), a leading provider of tools and services for drug discovery and life sciences research, today introduced Living Image 4.0 softwa
Breaking Biology Technology:Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Caliper Life Sciences Launches Living Image(R) 4.0 Software 2
...all/ - YM BioSciences Inc.,(AMEX: YMI , TSX: YM, ...velops and commercializes differentiated products ... completed accrual in the first 50-patient,cohort ...n with irinotecan,for the treatment of colorectal ... consistent with data from previous trials of nimo...
...eutics, Inc.,a biopharmaceutical company developin... announced the appointment of Colin Reisner, MD, F...r and Executive Vice,President of Clinical Develop...e position of Vice President, Regulatory Affairs a...nd Michael as we continue to build,our team with e...
..., a privately,held orthobiologic company, announce...e Finance Forum in San Francisco, CA from January ... CEO of ISTO, will present on,Tuesday, January 8th...ake,Hotel at 450 Powell St. Information about the ...www.onemedplace.com ., ISTO,s rich product pipeli...
Other Biology Technology:YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL 3Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs 2Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs 3
(Date:12/3/2009)The UK leads the world when it comes to investment in energy efficient technologies research, but Engineering and Physical Sciences Research Council (EPSRC) Chief Executive Dave Delpy believes that mo
(Date:12/3/2009)The 30-year record low in Antarctic snowmelt that occurred during the 2008-09 austral summer was likely due to concurrent strong positive phases for two main climate drivers, ENSO (El Nio - Southern O
(Date:12/2/2009)PHILADELPHIA Less acculturated Latino men have a more difficult time quitting smoking than those who are more acculturated to U.S. culture, but acculturation has no affect on Latinas odds of quitting
Breaking Biology News(10 mins):Research is vital to a cleaner, greener, low carbon future 2CCNY professor foresees rising Antarctic snowmelt 2Acculturation affects smoking cessation success among Latinos 2Blue Cross and Blue Shield of Floridas Power of the Human Voice Campaign Wins Prestigious DMA International ECHO Gold Award 60266 1Blue Cross and Blue Shield of Floridas Power of the Human Voice Campaign Wins Prestigious DMA International ECHO Gold Award 60266 2NIEHS awards Recovery Act funds to address bisphenol A research gaps 10565 1NIEHS awards Recovery Act funds to address bisphenol A research gaps 10565 2NIEHS awards Recovery Act funds to address bisphenol A research gaps 10565 3NIEHS awards Recovery Act funds to address bisphenol A research gaps 10565 4NIEHS awards Recovery Act funds to address bisphenol A research gaps 10565 5NIEHS awards Recovery Act funds to address bisphenol A research gaps 10565 6NIEHS awards Recovery Act funds to address bisphenol A research gaps 10565 7NIEHS awards Recovery Act funds to address bisphenol A research gaps 10565 8New Clues to How Fish Oils Help Arthritis Patients 60263 1New Clues to How Fish Oils Help Arthritis Patients 60263 2
...wheat stem sawfly natural enemies in demand, Monta...g ways of increasing their availability. , This ...study that involved mass-rearing parasitic wasps t...e interior of developing wheat plants. The team in...te Godshen Pallipparambil-Robert and undergraduate...
...niversity of Cincinnati (UC) has received $2.4 mil...stimulate the body,s natural defense system to cau...iseases. , Michael Borchers, PhD, believes long-t...y activate a specific receptor--known as NKG2D--in...k stressed (damaged) lung tissue. , "When tissue...
...iscovery of a DNA marker for two key rust resistan...ld to breed more effective rust resistant wheat va...d together and provide wheat plants with improved ...major diseases of wheat in Australia and worldwide...agudah, says various types of rust resistance have...
Other Biology News:Rearing an army to save wheat 2Rearing an army to save wheat 3Environmental toxins may cause body's defenses to worsen lung disease 2Environmental toxins may cause body's defenses to worsen lung disease 3Elusive rust resistance genes located 2
...oduced by a patented microwave process which makes..., even cell attachment, increased cell growth and ...th uunder difficult conditions, including reduced ...ovide a more ecominic alternative to expensive and...
...es are designed for quick and easy protein purific...re two 0.25mm holes laser cut at the conical ends ... incubation of the gel matrix with buffer, during ...the buffer. Following a centrifugation step, the p...
...-art in permanent mounting media. It is designed f...al organic insoluble substrates such as diaminoben... organic solvent compatible chromogen substrates o...y and cytology applications using manual and autom...
...ndustry's first siRNA sequence design software in ...ls consistent with new experimental strategies and... With the introduction of our new, enhanced, and e...to offer the most significant advancement in RNAi ...
Biology Products: